Although we did not directly show that blocking the FGF2/FGFR axis had an effect on tumor growth, it was recently shown that ponatinib, a dual KIT and FGFR inhibitor, caused much stronger inhibition of KIT-mutation-bearing melanoma in vivo than imatinib agreeing with our results [28]. Here, KIT is linked to neoplasm.